Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25324182 | 1.00 | RIPK1 (0.40) | RIPK1TACR1RORCNR1H2NR1H3 | |
| SCHEMBL30522896 | 1.00 | RIPK1 (0.40) | RIPK1TACR1RORCNR1H2NR1H3 | |
| SCHEMBL25326627 | 1.00 | RIPK1 (0.40) | RIPK1TACR1RORCNR1H2NR1H3 | |
| SCHEMBL25326625 | 1.00 | RIPK1 (0.40) | RIPK1TACR1RORCNR1H2NR1H3 | |
| SCHEMBL30523072 | 0.91 | TACR1 (0.35) | RIPK1TACR1RORCNR1H2NR1H3 | |
| SCHEMBL30522995 | 0.90 | TACR1 (0.35) | RIPK1TACR1RORCNR1H2NR1H3 | |
| SCHEMBL25327429 | 0.88 | NR1H2 (0.48) | RIPK1RORCNR1H2NR1H3GPR119 | |
| SCHEMBL25327427 | 0.88 | NR1H2 (0.48) | RIPK1RORCNR1H2NR1H3GPR119 | |
| SCHEMBL25325447 | 0.88 | RIPK1 (0.53) | RIPK1RORCNR1H2NR1H3 | |
| SCHEMBL25325443 | 0.88 | RIPK1 (0.53) | RIPK1RORCNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | RIPK1 4782/4885TACR1 369/4885RORC 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.